Who Exports Pioglitazone from India — 115 Suppliers Behind a $37.3M Market
India's pioglitazone export market is supplied by 115 active exporters who collectively shipped $37.3M across 2,674 shipments. AUROBINDO PHARMA LTD leads with a 40.7% market share, followed by AUROBINDO PHARMA LIMITED and INTAS PHARMACEUTICALS LIMITED. The top 5 suppliers together control 74.2% of total export value, reflecting a concentrated market structure.
Top Pioglitazone Exporters from India — Ranked by Export Value
AUROBINDO PHARMA LTD is the leading pioglitazone exporter from India, holding a 40.7% share of the $37.3M market across 2,674 shipments from 115 exporters. The top 5 suppliers — AUROBINDO PHARMA LTD, AUROBINDO PHARMA LIMITED, INTAS PHARMACEUTICALS LIMITED, MACLEODS PHARMACEUTICALS LTD, AJANTA PHARMA LIMITED — collectively control 74.2% of total export value, indicating a highly concentrated market. Individual shares are: AUROBINDO PHARMA LTD (40.7%), AUROBINDO PHARMA LIMITED (10.8%), INTAS PHARMACEUTICALS LIMITED (9.1%), MACLEODS PHARMACEUTICALS LTD (8.9%), AJANTA PHARMA LIMITED (4.7%).
Top Pioglitazone Exporters from India
Ranked by export value · 115 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | AUROBINDO PHARMA LTD PIOGLITAZONE TABLETS 30 MGPIOGLITAZONE HYDROCHLORIDE TABLETS 30MG 500'SPIOGLITAZONE HYDROCHLORIDE TABLETS 30MG 30'S | $15.2M | 4 | 40.7% |
| 2 | AUROBINDO PHARMA LIMITED PIOGLITAZONE TABLETS 30 MGPIOGLITAZONE HYDROCHLORIDE TABLETS 30MG 500'SPIOGLITAZONE HYDROCHLORIDE TABLETS 30MG 30'S | $4.0M | 5 | 10.8% |
| 3 | INTAS PHARMACEUTICALS LIMITED PH.DRU.& MED.: PIOGLITAZONE 15MG TABLETSPH.DRU.& MED.: PIOGLITAZONE 30MG TABLETSPHARM.DRUGS&MEDI.PIOGLITAZONE 15MG 2X14T | $3.4M | 11 | 9.1% |
| 4 | MACLEODS PHARMACEUTICALS LTD PIOGLITAZONE TABLETS 30 MGPIOGLITAZONE HYDROCHLORIDE TABLETS 30MG 500'SPIOGLITAZONE HYDROCHLORIDE TABLETS 30MG 30'S | $3.3M | 2 | 8.9% |
| 5 | AJANTA PHARMA LIMITED MEDICAMENTS - PIOGLITAZONE (AS HYDROCHLOTRIPRIDE 2 - TAX INVOICE NO: 705202586 DT: | $1.8M | 2 | 4.7% |
| 6 | MICRO LABS LIMITED MEDICAMENTS - PIOGLITAZONE (AS HYDROCHLOTRIPRIDE 2 - TAX INVOICE NO: 705202586 DT: | $1.6M | 9 | 4.2% |
| 7 | IND SWIFT LIMITED PIOGLITAZONE TABLETS 30 MGPIOGLITAZONE HYDROCHLORIDE TABLETS 30MG 500'SPIOGLITAZONE HYDROCHLORIDE TABLETS 30MG 30'S | $1.2M | 8 | 3.3% |
| 8 | MACLEODS PHARMACEUTICALS LIMITED PIOGLITAZONE TABLETS 30 MGPIOGLITAZONE HYDROCHLORIDE TABLETS 30MG 500'SPIOGLITAZONE HYDROCHLORIDE TABLETS 30MG 30'S | $1.2M | 1 | 3.3% |
| 9 | ARISTO PHARMACEUTICALS PRIVATE LIMITED | $721.0K | 6 | 1.9% |
| 10 | DR.REDDY'S LABORATORIES LTD DIAVISTA 30 MG TABS (PIOGLITAZONE HYDROCDIAVISTA 30 MG TABS(PIOGLITAZONE HYDROCHDIAVISTA 30MG TABLETS 2X10S PIOGLITAZONE | $683.3K | 1 | 1.8% |
| 11 | MEDLEY PHARMACEUTICALS LIMITED MEDICAMENTS - PIOGLITAZONE (AS HYDROCHLOTRIPRIDE 2 - TAX INVOICE NO: 705202586 DT: | $616.1K | 2 | 1.7% |
| 12 | TORRENT PHARMACEUTICALS LTD PIOGLITAZONE HYDROCHLORIDE TABLETS 30MGPIOGLITAZONE HYDROCHLORIDE TABLETS 30MG 1X10SPIOGLITAZONE HYDROCHLORIDE TABLETS 30MG 1X10'S | $493.8K | 3 | 1.3% |
| 13 | INTAS PHARMACEUTICALS LTD PH.DRU.& MED.: PIOGLITAZONE 15MG TABLETSPH.DRU.& MED.: PIOGLITAZONE 30MG TABLETSPHARM.DRUGS&MEDI.PIOGLITAZONE 15MG 2X14T | $385.6K | 7 | 1.0% |
| 14 | MYLAN LABORATORIES LIMITED | $295.0K | 1 | 0.8% |
| 15 | CIPLA LIMITED | $281.3K | 1 | 0.8% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Pioglitazone exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Aurobindo Pharma Limited | Approved | Yes (September 2023) | Yes | Multiple | WHO GMP approval for Unit IV in September 2023; FDA warning letter issued in Jun |
| Intas Pharmaceuticals Limited | Approved | Yes | Yes | Multiple | FDA warning letter in December 2022 for Sanand facility due to data falsificatio |
| Ajanta Pharma Limited | Approved | Yes | Yes | Multiple | Operates US FDA-approved facilities; no FDA warning letters reported. |
| Torrent Pharmaceuticals Limited | Approved | Yes | Yes | Multiple | FDA warning letter in May 2011; subsequent compliance achieved. |
| Micro Labs Limited | Approved | Yes | Yes | Multiple | Operates GMP-compliant facilities; no FDA warning letters reported. |
| Dr. Reddy's Laboratories Ltd | Approved | Yes | Yes | Multiple | FDA warning letter in November 2019; subsequent compliance achieved. |
| Cipla Limited | Approved | Yes | Yes | Multiple | Operates US FDA-approved facilities; no FDA warning letters reported. |
| Macleods Pharmaceuticals Limited | Approved | Yes | Yes | Multiple | Operates US FDA-approved facilities; no FDA warning letters reported. |
| Mylan Laboratories Limited | Approved | Yes | Yes | Multiple | FDA warning letter in November 2019; subsequent compliance achieved. |
| Ind-Swift Limited | Approved | Yes | Yes | Multiple | Operates US FDA-approved facilities; no FDA warning letters reported. |
TransData Nexus reviewed the regulatory standing of 10 leading Pioglitazone exporters from India. 10 hold US FDA facility approvals, 10 maintain WHO-GMP certification, and 10 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Pioglitazone sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," hosts numerous pharmaceutical companies specializing in active pharmaceutical ingredients (APIs). Aurobindo Pharma Limited, headquartered in Hyderabad, operates multiple manufacturing facilities in the region, producing a wide range of APIs and formulations. Their facilities have received approvals from major regulatory bodies, including the US FDA and UK MHRA.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its pharmaceutical formulations industry. Intas Pharmaceuticals Limited, based in Ahmedabad, operates several manufacturing facilities in the area, focusing on formulations across various therapeutic segments. Their facilities are approved by international regulatory agencies such as the US FDA and EMA.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for pharmaceutical products. Macleods Pharmaceuticals Ltd, with operations in this region, contributes significantly to pharmaceutical exports. Their manufacturing units are equipped to produce a diverse range of formulations, catering to both domestic and international markets.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh is a prominent pharmaceutical manufacturing zone, benefiting from tax incentives. Companies like Micro Labs Limited have established manufacturing units here, leveraging the favorable tax environment to produce cost-effective pharmaceutical products for export.
5Sourcing Recommendations
- Diversify Supplier Base: While Aurobindo Pharma Ltd is the leading exporter of Pioglitazone, consider engaging with other top exporters such as Intas Pharmaceuticals Limited and Macleods Pharmaceuticals Ltd to mitigate supply chain risks.
- Assess Manufacturing Capabilities: Evaluate the manufacturing facilities of potential suppliers, ensuring they have the capacity and regulatory approvals to meet quality standards.
- Monitor Regulatory Compliance: Regularly review the compliance status of suppliers with international regulatory bodies like the US FDA and EMA to ensure uninterrupted supply.
- Leverage Regional Advantages: Consider sourcing from regions like Baddi-Nalagarh for cost benefits due to tax incentives, while ensuring product quality and reliability.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Pioglitazone exporters from India
Aurobindo Pharma Limited — Aurobindo Pharma acquires Khandelwal Labs' non-oncology prescription business for ₹325 crore
Aurobindo Pharma, through its wholly owned subsidiary Auro Pharma Limited, acquired the non-oncology prescription business of Mumbai-based Khandelwal Laboratories Pvt Ltd for ₹325 crore. The acquisition includes 23 established brands across 67 stock-keeping units in pain management and anti-infective segments, supported by a field force of approximately 470 personnel and a distribution network of over 1,600 stockists across India. IMPACT: This acquisition is expected to strengthen Aurobindo Pharma's domestic market presence, potentially enhancing its Pioglitazone export capabilities.
Impact: This acquisition is expected to strengthen Aurobindo Pharma's domestic market presence, potentially enhancing its Pioglitazone export capabilities.
Aurobindo Pharma USA Inc. — Aurobindo Pharma USA enters collaboration for respiratory product development
Aurobindo Pharma's wholly owned subsidiary, Aurobindo Pharma USA Inc., entered into a collaboration and license agreement with a global pharmaceutical company for the development and commercialization of specific products in the respiratory therapeutic area. The agreement includes a cost-sharing arrangement with an overall cap of $90 million for Aurobindo over the development period. IMPACT: While focused on respiratory products, this collaboration may indirectly benefit Aurobindo's overall export strategy, including Pioglitazone.
Impact: While focused on respiratory products, this collaboration may indirectly benefit Aurobindo's overall export strategy, including Pioglitazone.
Aurobindo Pharma Limited — Aurobindo Pharma to acquire Lannett Company for $250 million
Aurobindo Pharma, through its US subsidiary, entered into a definitive agreement to acquire Lannett Company LLC for $250 million. Lannett, a US-based generic pharmaceuticals manufacturer, reported revenue of $306 million in FY25. The acquisition aims to expand Aurobindo's US manufacturing capacity and portfolio, particularly in ADHD therapies and complex controlled substances. IMPACT: This acquisition is expected to enhance Aurobindo's US market presence, potentially boosting Pioglitazone exports.
Impact: This acquisition is expected to enhance Aurobindo's US market presence, potentially boosting Pioglitazone exports.
Common Questions — Pioglitazone Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which pioglitazone supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, AUROBINDO PHARMA LTD leads with 547 recorded shipments worth $15.2M. AUROBINDO PHARMA LIMITED (161 shipments) and INTAS PHARMACEUTICALS LIMITED (473 shipments) are also established high-volume exporters.
Q How many pioglitazone manufacturers are there in India?
India has 115 active pioglitazone exporters with a combined export market of $37.3M across 2,674 shipments to 70 countries. The top 5 suppliers hold 74.2% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for pioglitazone from India?
Average FOB unit price: $0.91 per unit, ranging from $0.00 to $78.88. Average shipment value: $13.9K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 115 verified Indian exporters of Pioglitazone ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 2,674 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 70 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2,674 Verified Shipments
115 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists